MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

December 1, 2026

Conditions

CardiomegalyNoonan Syndrome

Interventions

DRUG

Trametinib tablet

Trametynib orally once daily in 0,025mg/kg dose

DRUG

Standard therapy

Disopiramide and Beta blockers orally

Trial Locations (1)

RECRUITING

Department of Paediatrics, The Medical University of Warsaw, Poland, Warsaw

All Listed Sponsors

lead

Medical University of Warsaw

OTHER